Using a Drug Candidate Screening Strategy to Mitigate Late-Stage Risk.

INTERFEROMETRY; DRUG efficacy; HIGH throughput screening (Drug development); CLINICAL drug trials; DRUG discovery; TIME; PHARMACEUTICAL technology; BIOAVAILABILITY; MEDICAL technology; INVESTIGATIONAL drugs; MARKETING; WORKFLOW; ENZYME-linked immunosorbent assay; INTERPROFESSIONAL relations; DRUG development; PATIENT safety; SURFACE plasmon resonance; GOAL (Psychology); SUCCESS

The article explores the use of a drug screening strategy to mitigate late-stage risk or failure. Topics discussed include challenges to early-stage drug candidate screening such as safety, bioavailability and efficacy, advancements for drug discovery bioanalytics including grating-coupled interferometry (GCI) and enzyme-linked immunosorbent assay, and ways to facilitate speed-to-market success of early drug screening strategy such as CGI data analysis and integration of development thinking.